Side-by-side comparison of AI visibility scores, market position, and capabilities
Sana Biotechnology develops engineered cell and gene therapies with fusogen delivery technology to treat serious diseases through in vivo and ex vivo approaches.
Sana Biotechnology is a publicly traded gene therapy company founded in 2018 by veterans of Juno Therapeutics and other leading cell therapy companies. The company is building technologies to repair or replace any gene in any cell, with a particular focus on its proprietary fusogen-based delivery platform that enables engineered cells to fuse with and deliver genetic material to specific target cells in the body. This approach could enable off-the-shelf cell therapies and in vivo gene editing without the need to harvest and engineer patient cells individually. Sana has programs targeting blood cancers, autoimmune diseases, and type 1 diabetes, exploring both in vivo gene delivery and ex vivo engineered cell therapies. The company went public through an IPO in 2021, raising substantial capital to advance its novel platform. Sana has formed research collaborations with academic institutions and pharmaceutical companies to advance specific programs. The company represents the cutting edge of cell and gene therapy with proprietary delivery technologies that could unlock new therapeutic approaches beyond what current viral vector and CRISPR systems enable.
CrowdStrike (CRWD) reported $3.95B ARR in FY2025 (ended Jan). Revenue $3.74B, up 29% YoY. Market cap ~$85B. 8,600+ employees. Austin, TX. AI-native cybersecurity platform. Charlotte AI for threat detection.
CrowdStrike is an AI-native cybersecurity company founded in 2011 by George Kurtz, Dmitri Alperovitch, and Gregg Marston and headquartered in Austin, Texas, that built the endpoint detection and response (EDR) category and has since expanded into the broadest cloud-native cybersecurity platform in the industry. The company was founded on the insight that traditional antivirus software — signature-based, retrospective, and endpoint-isolated — could not keep pace with sophisticated adversaries operating at machine speed. CrowdStrike's founding architecture, the Falcon platform, was designed cloud-native from day one: a single lightweight agent on the endpoint feeding a cloud-based AI that learns from trillions of security events across every customer simultaneously. The company trades on Nasdaq under the ticker CRWD.\n\nThe CrowdStrike Falcon platform consolidates more than 28 security modules across endpoint security, identity threat protection, cloud security, next-gen SIEM and log management, threat intelligence, and managed detection and response — all delivered through a single agent and unified console. The AI at the platform's core, Charlotte AI, provides conversational security operations, automated investigation, and AI-generated threat summaries that reduce analyst workload. CrowdStrike's threat intelligence team, Adversary Intelligence, tracks and names nation-state and criminal threat actors globally, giving customers predictive insight into campaigns before they hit their environments.\n\nCrowdStrike reported $3.95 billion in annual recurring revenue (ARR) for FY2025 and total revenue of $3.74 billion, up 29% year over year, with a market capitalization of approximately $85 billion. The company has 8,600+ employees and counts a substantial share of the Fortune 500 and global governments as customers. Despite the July 2024 sensor update incident that caused a significant IT outage affecting millions of Windows systems globally, CrowdStrike's customer retention remained strong — a testament to the platform's depth of integration and the switching costs built into its consolidated architecture.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.